JP7249950B2 - ヘテロ環化合物 - Google Patents

ヘテロ環化合物 Download PDF

Info

Publication number
JP7249950B2
JP7249950B2 JP2019553090A JP2019553090A JP7249950B2 JP 7249950 B2 JP7249950 B2 JP 7249950B2 JP 2019553090 A JP2019553090 A JP 2019553090A JP 2019553090 A JP2019553090 A JP 2019553090A JP 7249950 B2 JP7249950 B2 JP 7249950B2
Authority
JP
Japan
Prior art keywords
group
alkyl
membered
substituted
substituents selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019553090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515575A (ja
JP2020515575A5 (https=
Inventor
伸之 松永
崇 中畑
雄太 田中
洋希 ▲高▼萩
泰史 宮本
玲 岡本
武 吉川
嘉人 寺尾
猛史 湯川
佳子 掛川
洋一 西川
輝文 高木
昌志 高橋
マラレディ・コマンドラ
リリー・クウォック
ジョアン・ミウラ
マーク・サバット
ニコラス・スコラー
ポール・タニス
ジョン・ティホネス
フォン・エイチ・ヴー
ハイシャ・ワン
シャオルン・ワン
淳也 白井
友洋 大川
善右 塩川
章人 渋谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardurion Pharmaceuticals Inc
Original Assignee
Cardurion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardurion Pharmaceuticals Inc filed Critical Cardurion Pharmaceuticals Inc
Publication of JP2020515575A publication Critical patent/JP2020515575A/ja
Publication of JP2020515575A5 publication Critical patent/JP2020515575A5/ja
Application granted granted Critical
Publication of JP7249950B2 publication Critical patent/JP7249950B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
JP2019553090A 2017-03-27 2018-03-23 ヘテロ環化合物 Active JP7249950B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762476970P 2017-03-27 2017-03-27
US62/476,970 2017-03-27
PCT/US2018/024043 WO2018183112A1 (en) 2017-03-27 2018-03-23 Heterocyclic compound

Publications (3)

Publication Number Publication Date
JP2020515575A JP2020515575A (ja) 2020-05-28
JP2020515575A5 JP2020515575A5 (https=) 2021-04-30
JP7249950B2 true JP7249950B2 (ja) 2023-03-31

Family

ID=63671942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553090A Active JP7249950B2 (ja) 2017-03-27 2018-03-23 ヘテロ環化合物

Country Status (9)

Country Link
US (2) US10543212B2 (https=)
EP (1) EP3600327A4 (https=)
JP (1) JP7249950B2 (https=)
KR (1) KR102638678B1 (https=)
CN (1) CN110799190B (https=)
AU (1) AU2018243691B2 (https=)
CA (1) CA3058182A1 (https=)
TW (1) TWI789381B (https=)
WO (1) WO2018183112A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110799190B (zh) * 2017-03-27 2024-04-19 卡都瑞恩医药有限公司 杂环化合物
WO2019126731A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2020068846A1 (en) * 2018-09-25 2020-04-02 Heterocyclic Compound Heterocyclic compound
JP7447098B2 (ja) * 2018-09-25 2024-03-11 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド アミノピリミジン化合物
WO2020140054A1 (en) 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
EP4048664A1 (en) * 2019-10-25 2022-08-31 Gilead Sciences, Inc. Glp-1r modulating compounds
ES3016132T3 (en) 2020-01-29 2025-05-08 Gilead Sciences Inc Glp-1r modulating compounds
IL296336A (en) * 2020-03-18 2022-11-01 Lg Chemical Ltd Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same
KR102563111B1 (ko) * 2020-03-18 2023-08-04 주식회사 엘지화학 Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법
JP7824282B2 (ja) 2020-09-28 2026-03-04 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
WO2022192428A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4304712A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2022216094A1 (ko) * 2021-04-08 2022-10-13 주식회사 엘지화학 Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법
IL306110A (en) 2021-04-21 2023-11-01 Gilead Sciences Inc Carboxy-benzimidazole glp-1r modulating compounds
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
WO2023130050A1 (en) * 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of pain
CN114621312B (zh) * 2022-03-24 2022-11-15 陕西师范大学 一种寡肽烷基侧链的选择性修饰方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004510707A (ja) 2000-08-08 2004-04-08 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 神経保護性の２−ピリジナミン組成物および関係する方法
JP2010523568A (ja) 2007-04-05 2010-07-15 アムジエン・インコーポレーテツド オーロラキナーゼ調節物質及び使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1054393B (en) 2000-09-20 2009-08-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
JP2007504229A (ja) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類
AU2008296479A1 (en) * 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
TW201016676A (en) * 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
GB0821307D0 (en) * 2008-11-21 2008-12-31 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
JP2014500254A (ja) 2010-11-09 2014-01-09 セルゾーム リミティッド Ｔｙｋ２阻害剤としてのピリジン化合物およびそのアザ類似体
US9216173B2 (en) 2011-10-05 2015-12-22 Merck Sharp & Dohme Corp. 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
HRP20180037T1 (hr) 2012-04-17 2018-03-23 Fujifilm Corporation Heterociklični spoj koji sadrži dušik ili njegovu sol
CN110799190B (zh) * 2017-03-27 2024-04-19 卡都瑞恩医药有限公司 杂环化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004510707A (ja) 2000-08-08 2004-04-08 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 神経保護性の２−ピリジナミン組成物および関係する方法
JP2010523568A (ja) 2007-04-05 2010-07-15 アムジエン・インコーポレーテツド オーロラキナーゼ調節物質及び使用方法

Also Published As

Publication number Publication date
KR20200027917A (ko) 2020-03-13
JP2020515575A (ja) 2020-05-28
EP3600327A4 (en) 2020-10-28
TWI789381B (zh) 2023-01-11
CA3058182A1 (en) 2018-10-04
AU2018243691A1 (en) 2019-10-24
US11197858B2 (en) 2021-12-14
KR102638678B1 (ko) 2024-02-19
AU2018243691B2 (en) 2022-05-12
CN110799190B (zh) 2024-04-19
US20180280389A1 (en) 2018-10-04
TW201904959A (zh) 2019-02-01
WO2018183112A1 (en) 2018-10-04
US20200230137A1 (en) 2020-07-23
EP3600327A1 (en) 2020-02-05
CN110799190A (zh) 2020-02-14
US10543212B2 (en) 2020-01-28

Similar Documents

Publication Publication Date Title
JP7249950B2 (ja) ヘテロ環化合物
US20230117295A1 (en) Nitrogen containing heterocycles as cdk12 inhibitors
JP7824282B2 (ja) 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用
JP2026010092A (ja) 複素環化合物
JP6706250B2 (ja) 複素環化合物
WO2020116662A1 (ja) シクロアルカン−１，３−ジアミン誘導体
JP7447098B2 (ja) アミノピリミジン化合物
EA052559B1 (ru) Конденсированные гетероарильные соединения и их применение в качестве ингибиторов camkii

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210316

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230320

R150 Certificate of patent or registration of utility model

Ref document number: 7249950

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250